前瞻性临床试验中弥漫大B细胞淋巴瘤的细胞起源分类与MYC/BCL2双表达状态的临床影响
在德国高级别非霍奇金淋巴瘤研究组的两项前瞻性随机试验中,对452例弥漫大B细胞淋巴瘤样本进行细胞起源分类、MYC/BCL2双表达及基因重排分析。结果显示细胞起源分类未能识别预后亚组,而MYC/BCL2双表达与较差生存相关。
要点
- 在RICOVER-60试验的R-CHOP治疗患者中,活化B细胞样与生发中心B细胞样弥漫大B细胞淋巴瘤的无事件生存、无进展生存和总生存均无显著差异。
- MYC/BCL2双表达状态在生发中心B细胞样亚组中与显著较差生存相关,但在活化B细胞样亚组中未观察到该关联。
- 在非双表达患者中,活化B细胞样亚组的5年无进展生存率低于生发中心B细胞样亚组(68% vs 85%,P=0.04)。
核心结论
- 在两项前瞻性随机弥漫大B细胞淋巴瘤试验中,细胞起源分类未能识别预后亚组,而MYC和BCL2双表达可预测较差生存。
- 未来在弥漫大B细胞淋巴瘤管理中的预后或预测生物标志物(如细胞起源)评估应在前瞻性临床试验中进行。
研究设计与样本
- 分析德国高级别非霍奇金淋巴瘤研究组两项前瞻性随机试验(RICOVER-60和R-MegaCHOEP)的452例福尔马林固定石蜡包埋样本。
- RICOVER-60为针对>60岁、所有IPI组患者的前瞻性随机研究;R-MegaCHOEP为针对≤60岁、年龄调整IPI 2,3患者的前瞻性随机研究。
- 采用Lymph2Cx检测进行细胞起源分类,免疫组化检测MYC和BCL2,荧光原位杂交检测MYC、BCL2和BCL6重排。
主要发现
- 细胞起源分类在414/452例样本中成功。
- 在RICOVER-60试验的R-CHOP治疗患者中,活化B细胞样 vs 生发中心B细胞样弥漫大B细胞淋巴瘤在无事件生存、无进展生存和总生存方面无显著差异。
- 调整国际预后指数因素的多变量分析中,活化B细胞样 vs 生发中心B细胞样的无事件生存HR为1.0(95%CI 0.6-1.6,P=0.93),无进展生存HR为1.1(95%CI 0.6-1.8,P=0.82),总生存HR为1.0(95%CI 0.6-1.8,P=0.96)。
- R-MegaCHOEP试验中观察到类似结果。
- 在R-CHOP治疗患者中,生发中心B细胞样亚组内双表达状态与显著较差生存相关,而活化B细胞样亚组内未观察到该关联。
关键数值与推荐
- 细胞起源分类成功例数:414/452例。
- 活化B细胞样 vs 生发中心B细胞样的无事件生存HR 1.0(95%CI 0.6-1.6,P=0.93)。
- 活化B细胞样 vs 生发中心B细胞样的无进展生存HR 1.1(95%CI 0.6-1.8,P=0.82)。
- 活化B细胞样 vs 生发中心B细胞样的总生存HR 1.0(95%CI 0.6-1.8,P=0.96)。
- 双表达活化B细胞样 vs 无双表达活化B细胞样的5年无进展生存率39%(95%CI 19%-59%) vs 68%(95%CI 52%-85%),P=0.03。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To explore the prognostic impact and interdependence of the cell-of-origin (COO) classification, dual expression (DE) of MYC and BCL2 proteins, and MYC, BCL2, and BCL6 translocations in two prospectively randomized clinical trials of patients with diffuse large B-cell lymphoma (DLBCL). Patients and Methods Overall, 452 formalin-fixed paraffin-embedded samples from two prospective, randomized DLBCL trials (RICOVER-60, prospective, randomized study for patients > 60 years, all IPI groups; and R-MegaCHOEP, prospective, randomized study for patients ≤ 60 years with age-adjusted IPI 2,3) of the German High-Grade Non-Hodgkin Lymphoma Study Group were analyzed with the Lymph2Cx assay for COO classification, with immunohistochemistry for MYC and BCL2, and with fluorescent in situ hybridization for MYC, BCL2, and BCL6 rearrangements. Results COO classification was successful in 414 of 452 samples. No significant differences with respect to COO (activated B-cell [ABC]-like DLBCL v germinal center B-cell [GCB]-like DLBCL) were observed in event-free survival, progression-free survival, and overall survival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in the RICOVER-60 trial. Also, no differences with respect to COO were observed in multivariable analyses adjusted for International Prognostic Index factors in event-free survival (hazard ratio [HR] of ABC-like disease v GCB-like disease, 1.0; 95% CI, 0.6 to 1.6; P = .93), progression-free survival (HR, 1.1; 95% CI, 0.6 to 1.8; P = .82), and overall survival (HR, 1.0; 95% CI, 0.6 to 1.8; P = .96). Similar results were observed in the R-MegaCHOEP trial. In patients treated with R-CHOP, DE status was associated with significantly inferior survival compared with nonDE within the GCB, but not within the ABC subgroup. DE status was associated with significantly inferior outcome compared with patients with ABC-like DLBCL without DE (5-year PFS rate, 39% [95% CI,19% to 59%] v 68% [95% CI, 52% to 85%]; P = .03) and compared with patients with GCB-like DLBCL without DE. When data from patients with nonDE were analyzed separately, the outcome of patients in the ABC subgroup was inferior to that of patients in the GCB subgroup (5-year PFS rate, 68% [95% CI, 52% to 85%] v 85% [95% CI, 74% to 96%]; P = .04). Conclusion COO profiling in two prospective randomized DLBCL trials failed to identify prognostic subgroups, whereas dual expression of MYC and BCL2 was predictive of poor survival. Evaluation of prognostic or predictive biomarkers in the management of DLBCL, such as the COO, within prospective clinical trials will be important in the future.
引用
- Staiger AM, Ziepert M, Horn H, et al. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. J Clin Oncol. 2017. PMID: 28525305. doi:10.1200/JCO.2016.70.3660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。